BioSpace News Archive

ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announced successful results from the conclusion of the non-inferiority study conducted on the GluCurve Pet CGM which was previously announced on February 10, 2022 and February 28, 2022.

TC Biopharm PLC, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, highlighted their intellectual property

Bearpac Medical, LLC announced that its Passio Pump Drainage System has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company.

BodiMetrics announced today the results of a 164 patient clinical study that compared their Prevention circul+ wearable ring device versus traditional polysomnography (PSG) test.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has entered into an exclusive license agreement with Kukbo Co. Ltd., a South Korean corporation, for oral opaganib[1] for the treatment of COVID-19, in South Korea.

Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company’s President and Chief Scientific Officer, will present recent clinical results today, Tuesday, March 15th, at the International Conference on Alzheimer’s (AD) and Parkinson’s Diseases (AD/PD 2022).

BostonGene Corporation and Thomas Jefferson University announced the online publication of the manuscript, “Tadalafil enhances immune response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma” in the American Association for Cancer Research journal Clinical Cancer Research.

MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A round that exceeded $2.5 million, including from existing investors.

Burning Rock Biotech Limited announced that the National Medical Products Administration approved Burning Rock’s Human Nine-Gene Mutation Joint Detection Kit as a class III medical device.

Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar Disorder.